Gastroesophageal Junction and Gastric Cancer
Clinical development activity includes treatment research in locally advanced and metastatic gastroesophageal junction cancer and gastric cancer, with attention to HER2-directed therapy and combination regimens used in first-line care.
- HER2-positive gastric malignancies
- Metastatic gastric cancer
- Gastroesophageal junction cancer
Research in this area is centered on antibody-based treatment strategies integrated with established chemotherapy backbones and immunotherapy-relevant combinations.
Advanced Non-Small Cell Lung Cancer
The sponsor also funds clinical research in advanced non-small cell lung cancer, with interest in novel oncology biologics evaluated for lung cancer treatment.
- Advanced NSCLC
- Lung cancer therapeutics
- Oncology biologics
This therapeutic area reflects activity in solid-tumor oncology, particularly for patients with advanced disease requiring systemic treatment options.
Monoclonal Antibody and Antibody-Based Oncology
Across its studies, the company shows a clear focus on monoclonal antibody development for cancer, including targeted agents designed for use alongside standard oncology treatments.
- Recombinant humanized antibodies
- Targeted cancer therapy
- Combination antibody regimens
These programs place emphasis on biologic approaches to tumor control in both upper gastrointestinal and thoracic malignancies.
Solid Tumor Clinical Development
The sponsor’s research landscape is concentrated in solid tumor oncology, with active studies spanning multiple countries and sites in Asia and other regions.
- Metastatic solid tumors
- Multicenter oncology trials
- Global cancer development
Its clinical portfolio is focused on cancers with significant unmet need, especially disease settings requiring systemic, targeted, and combination treatment approaches.
